000 02312cam a2200421 i 4500
999 _c121657
_d121657
_x1
001 121657
003 ES-MaUEC
005 20230228040218.0
006 a|||| o|||| 00| 0
007 cr cn |||mnn||
008 100721s2011 paua ob 001 0 eng d
010 _a 2010031113
016 7 _a101536380
_2DNLM
020 _a9780781796934
020 _a0781796938
035 _a(OCoLC)ocn650953409
040 _aDNLM/DLC
_cDLC
_dYDX
_dNLM
_dYDXCP
_dCDX
_dDLC
_bspa
042 _apcc
050 4 _aRC271.R26
_b2011 EB
060 0 0 _a2011 I-553
060 1 0 _aQZ 269
245 0 0 _aTargeted radionuclide therapy
_ceditor, Tod W. Speer
264 1 _aPhiladelphia
_bLippincott Williams & Wilkins
_c2011
300 _a1 recurso en línea (XVII, 537 páginas)
_bilustraciones
336 _2rdacontent
_aTexto
_btxt
337 _2rdamedia
_aelectrónico
_bc
338 _2rdacarrier
_arecurso electrónico
_bcr
504 _aIncluye referencias bibliográficas e índice
520 _a"Radioimmunotherapy, also known as systemic targeted radiation therapy, uses antibodies, antibody fragments, or compounds as carriers to guide radiation to the targets. It is a topic rapidly increasing in importance and success in treatment of cancer patients. This book represents a comprehensive amalgamation of the radiation physics, chemistry, radiobiology, tumor models, and clinical data for targeted radionuclide therapy. It outlines the current challenges and provides a glimpse at future directions. With significant advances in cell biology and molecular engineering, many targeting constructs are now available that will safely deliver these highly cytotoxic radionuclides in a targeted fashion"--Provided by publisher.
988 _aLWW Classic Book Collection_2020
650 7 _aCáncer
_xRadioterapia
_2embne
_9186645
650 2 7 _aIsótopos radiactivos
_2embne
_9672880
700 1 _aSpeer, Tod W.
_eeditor literario
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https%3A%2F%2Fovidsp.ovid.com%2Fovidweb.cgi%3FT%3DJS%26NEWS%3Dn%26CSC%3DY%26PAGE%3Dbooktext%26D%3Dbooks%26AN%3D01437576%24%26XPATH%3D%2FPG%280%29%26EPUB%3DY
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942 _2lcc
_cLE
998 _b08/2020
_dz
_eu
_zSI